BioCryst Gets a Hold Rating from Needham

By Ryan Adsit

Needham analyst Serge Belanger reiterated a Hold rating on BioCryst (NASDAQ: BCRX) yesterday. The company’s shares opened today at $5.92.

Belanger commented:

“Shire (SHPG) reported positive results from the ph 3 HELP trial evaluating lanadelumab (fka SHP643) as a prophylactic HAE treatment. Lanadelumab, an antibody that binds and inhibits plasma kallikrein, is formulated for subcutaneous administration and has a long half-life (~14 days) that enables once- or twice-monthly dosing. The HELP trial met all of its endpoints; monthly attack rate reduction vs. placebo for all dosing regimens ranged from 73% – 87% (p<0.001). A BLA filing for lanadelumab is expected in late-2017/early-2018. BCRX's BCX7353, a daily orally-administered HAE prophylactic candidate, is currently under evaluation in the ph 2 APeX-1 trial. Positive interim results reported in late-Feb showed that BCX7353 led to a ~52% HAE attack rate reduction (p=0.035, ITT), with results showing a dichotomy of efficacy between peripheral attacks (~88% reduction) and abdominal attacks (~24% reduction). Additional APeX-1 cohorts evaluating lower-doses of BCX7353 are expected to report in 2Q17. These data should provide clarity on the efficacy/tolerability profile of BCX7353 and help shed some light on its potential role in HAE prophylaxis."

According to, Belanger is a 2-star analyst with an average return of 0.1% and a 35.6% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Adamas Pharmaceuticals, and Amag Pharmaceuticals.

BioCryst has an analyst consensus of Moderate Buy, with a price target consensus of $8.67.

The company has a one year high of $9.25 and a one year low of $2.60. Currently, BioCryst has an average volume of 1.83M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioCryst Pharmaceuticals, Inc. engages in the research, development, and commercialization of biopharmaceutical products. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.